Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-05-04
2001-11-20
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S361000, C514S415000, C514S466000, C514S631000, C514S637000, C514S469000, C549S366000, C549S440000, C548S125000, C548S127000, C564S225000, C564S244000
Reexamination Certificate
active
06319944
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to novel aryl amidines, compositions containing such compounds and methods of treating neurological and neurodegenerative diseases. In particluar, this invention relates to amidines that are useful as NMDA NR2B antagonists. The compounds of the instant invention are thus useful for relieving, treating or preventing neurological and neurodegenerative diseases, including pain, (and in particular neuropathic pain), epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, Alzheimer's Disease, Huntington's Disease and Parkinson's Disease.
Evidence for the analgesic effects of NMDA receptor antagonists in man is strong. Ion channel antagonists such as ketamine and dextromethorphan produce hallucinations, sedation, and ataxia at doses only marginally higher than the analgesic dose. The NR2B receptor is found pre-synaptically on most small sensory fibres entering the spinal dorsal horn as well as postsynaptically unlike other NMDA receptors which are exclusively postsynaptic. This restricted distribution lowers the probability of side effects and makes the target highly attractive for the treatment of neuropathic and other pain conditions.
Glutamate plays a key role in processes related to chronic pain and pain-associated neurotoxicity, largely acting through N-methyl-D-aspartate (NMDA) receptors. Much evidence points to the involvement of NMDA receptors in the development and maintenance of neuropathic pain. NMDA receptor antagonists, for example ketamine, dextromethorphan and CPP (3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) have been reported to produce symptomatic relief in a number of neuropathies including postherpetic neuralgia, central pain caused by spinal cord injury and phantom limb pain (Kristensen et al., 1992; Eide et al., 1995; Knox et al., 1995; Max et al., 1995). However, at analgesic doses, psychotomimetic effects that include dizziness, headache, hallucinations, dysphoria and disturbances of cognitive and motor function prohibit their widespread use. To exploit NMDA receptor antagonists as possible treatment modalities for neuropathic pain, it is necessary to develop new agents with a reduced side-effect profile.
Native NMDA receptors are heterodimers composed of an NMDA R1 (NR1) subunit and at least one NMDA R2 (NR2) subunit. Receptor cloning strategies have identified multiple NMDA receptor subunits in the CNS including the NR1 subfamily (with eight isoforms derived from alternative splicing of a single gene) and four NR2 subunits (A, B, C, and D) each encoded by a single gene (for review, see Whiting & Priestly, 1996). Functional receptors have different physiological and pharmacological properties and are differentially distributed in the mammalian CNS, demonstrating the functional heterogeneity of NMDA receptors (Ishii et al., 1993; Wenzel et al., 1995; Laurie et al., 1997).
NR1 is found throughout the brain whereas NR2 subunits show a differential distribution. In particular whereas NR2C is heavily expressed and NR2A is moderately expressed in the cerebellum, there is negligible expression of NR2B in this structure. Immunocytochemical studies have demonstrated a restricted distribution of the NR2B subunit, with moderate labeling of fibres in laminas I and II of the dorsal horn suggesting a presynaptic location on primary afferent fibres and possible involvement in pain transmission (Boyce et al., 1999). The patterns of staining observed in the spinal cord, together with the data showing negligible expression of NR2B in the cerebellum, suggest that NR2B antagonists may possess antinociceptive effects, but with a reduced side effect profile than non-competitive NMDA antagonists or glycine site antagonists.
The NR2B selective antagonist CP-101,606 has been reported to possess antinociceptive activity in animal assays of inflammatory hyperalgesia (Taniguchi et al., 1997; Sakurada et al, 1998). In an animal assay of inflammatory hyperalgesia (carrageenan-induced mechanical hyperalgesia) NR2B antagonists CP-101,606 and Ro 25-6981 possess antinociceptive activity with a significant separation between analgesic doses and those which induced motor impairment (Boyce et al., 1999). NR2B antagonists are active in a wide range of animal nociceptive assays, suggesting a clinical utility for other painful conditions in addition to those caused by nerve damage. Moreover these compounds may have a reduced propensity to elicit the ataxic effects of ketamine and other NMDA ion channel antagonists.
There is a wealth of in vitro and animal model data which suggests that changes in the glutamatergic system (receptors, uptake, release) increase neuronal sensitivity to previous physiological stimuli and thereby trigger secondary neuronal damage. The primary pathology underlying the generation of symptoms in Parkinson's disease is degeneration of dopaminergic neurons of the nigrostriatal pathway (Hornykiewcz, 1966). Subsequent to loss of striatal dopamine, a series of changes in activity of the basal ganglia circuitry arise, including increased activity in striatal outputs to the lateral segment of the globus pallidus. Overactivity of the striatolateral pallidal pathway is thought to be responsible for the generation of parkinsonian symptoms. It has been demonstrated that selective blockade of NR2B-containing NMDA receptors with the polyamine antagonists ifenprodil and eliprodil cause a significant increase in locomoter activity in a rodent model (Nash et al., 1999) and ifenprodil has demonstrated activity in a primate model of Parkinson's disease (Mitchell et al., 1995).
Based upon the foregoing, one object of the present invention is to provide NR2B active compounds with a reduced side effect profile compared to conventional agents.
Another object is to expoit the NR2B pathway with new treatment modalities.
Another object is to provide compounds that are useful in controlling neuropathic pain. These and other objectives will be obvious to those of ordinary skill from the teachings contained herein.
SUMMARY OF THE INVENTION
A compound represented by formula I:
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
each R
1
independently represents a member selected from the group consisting of: halo, C
1-7
alkyl, haloC
1-7
alkyl, OH, OC
1-7
alkyl, and haloC
1-7
alkoxy,
and Z represents a member selected from the group consisting of: H, halo, C
1-7
alkyl, haloC
1-7
alkyl, OH, haloC
1-7
alkoxy and aryl,
or one R
1
group and Z or two R
1
groups taken in combination represent a fused aryl, heteroaryl or heterocyclyl group, said fused group being optionally substituted with 1-4 groups selected from OH, halo, C
1-7
alkyl, sulfonyl, cyano, OC
1-7
alkyl, haloC
1-7
alkyl and haloC
1-7
alkoxy and the remaining R
1
groups are as originally defined;
R
3
and R
4
independently represent H, C
1-7
alkyl, C
2-4
alkenyl, C
2-4
alkynyl, aryl or heterocyclyl; and
R
2
represents H, aryl or heteroaryl, said aryl or heteroaryl being optionally substituted with 1-3 groups selected from: halo, OH, C
1-7
alkyl, OC
1-7
alkyl, haloC
1-7
alkyl and haloC
1-7
alkoxy.
Pharmaceutical compositions and methods of treatment are also included.
DETAILED DESCRIPTION
The present invention includes compounds represented by formula I:
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
each R
1
independently represents a member selected from the group consisting of: halo, C
1-7
alkyl, haloC
1-7
alkyl, OH, OC
1-7
alkyl, and haloC
1-7
alkoxy,
and Z represents a member selected from the group consisting of: H, halo, C
1-7
alkyl, haloC
1-7
alkyl, OH, haloC
1-7
alkoxy and aryl,
or one R
1
group and Z or two R
1
groups taken in combination represent a fused aryl, heteroaryl or heterocyclyl group, said fused group being optionally substituted with 1-4 groups selected from OH, halo, C
1-7
alkyl, sulfonyl, cyano, OC
1-7
alkyl, haloC
1-7
alkyl and haloC
1-7
alkoxy and the remaining R
1
groups are as originally defined;
R
3
and R
4
independently represent H, C
1-7
alkyl, C
2-
Claiborne Christopher F.
Curtis Neil R.
Kulagowski Janusz
Libby Brian
Liverton Nigel J.
Lee Shu M.
Merck & Co. , Inc.
Owens Amelia
Rose David L.
LandOfFree
Aryl amidines, compositions containing such compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl amidines, compositions containing such compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl amidines, compositions containing such compounds and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2601400